Cancer Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cancer Diagnostics Market Trends and Insights

Increasing Government-Funded Screening Programs

Governments now treat cancer screening as essential infrastructure because early detection reduces treatment spending by as much as 60–80% compared with late-stage therapy. China’s Healthy China 2030 plan also seeks to alleviate the financial burden on citizens by recommending reducing individual out-of-pocket health costs to 25% by 2030. To support these goals, China is heavily investing in biotech innovation and digital health, specifically targeting 3 registered doctors and 4.7 registered nurses per 1,000 residents by 2030. In 2024, the Health Resources and Services Administration (HRSA) awarded nearly USD 9 million to 18 health centers through the Accelerating Cancer Screening (AxCS) program to improve access to screening services, such as colorectal cancer screening. In India, a nationwide screening campaign for non-communicable diseases (NCDs), including oral, breast, and cervical cancers, was launched from February 20, 2025, to March 31, 2025, targeting individuals aged 30 and above across the country. Furthermore, the Union Budget 2025-26 announced plans to establish 200 Day Care Cancer Centres in district hospitals across India to decentralize cancer care and improve accessibility. Collectively, these programs elevate baseline testing volumes, enhance vendor visibility, and make long-term contracts contingent on interoperability with national health information. exchanges.   

Rising Global Cancer Incidence & Aging Population

In 2025, around 2 million new cancer cases and 0.6 million cancer deaths were projected to occur in the United States. The share of the global population aged 65 and older will move from 10% in 2025 to 16% by 2050, pushing demand in regions where oncologist density remains below OECD norms.^{[1]United Nations Population Division, “World Population Prospects,” UN.ORG} Japan and South Korea, with median ages above 48, now reimburse liquid-biopsy panels alongside biennial imaging for citizens over 40, aiming to offset specialist shortages through automation. China’s oncologist-to-population ratio is half the OECD average, prompting rapid adoption of AI-assisted pathology platforms that maintain throughput despite workforce gaps. The demographic trajectory ensures sustained test volume growth, but it also underscores the urgency of decision-support software to prevent bottlenecks.

Rapid Adoption of Liquid-Biopsy & ctDNA Tests

Between 2024 and 2026, liquid biopsies progressed from research tools to reimbursed clinical assays after evidence showed they detect recurrence an average of 8.7 months earlier than imaging.^{[2]New England Journal of Medicine, “Circulating Tumor DNA Detection,” NEJM.ORG} The U.S. FDA granted breakthrough status to four multi-cancer early-detection tests in 2025, and Medicare finalized nationwide coverage in January 2026 for 41 million beneficiaries. Germany and France followed with national reimbursement in 2025, confirming a pan-Atlantic consensus on clinical utility. Guardant Health’s Guardant360 CDx volumes climbed 67% year-on-year in H1 2025, reflecting oncologists’ preference for non-invasive profiling. Turnaround times fell to five days by 2026 after laboratories automated DNA extraction and library prep, making blood-based testing viable for same-week treatment planning.

Expansion of Point-of-Care Imaging & Diagnostics

Point-of-care devices move testing from hospital core labs to clinics, pharmacies, and even mobile vans, shortening clinical decision loops to under one hour. GE HealthCare introduced a handheld ultrasound in 2025 with AI lesion-detection that delivered 91% sensitivity for breast masses in rural U.S. trials. Siemens Healthineers followed with a benchtop immunoassay system in 2026 that processes 40 samples per hour, appealing to urgent-care centers facing space limits. Although U.S. fee-for-service payments remain lower for point-of-care tests, accountable-care organizations favor them because faster results cut referral losses and improve adherence.  

High Cost of Advanced Molecular Diagnostics

Next-generation sequencing and liquid-biopsy assays list between USD 2,800 and USD 5,000, a level unaffordable in regions where annual health spending per capita is below USD 500. In India, a USD 3,500 genomic panel equals 1.4 times the median monthly household income, restricting uptake to metropolitan centers. Kenya’s public insurance pays only USD 12 for a complete blood count and offers no coverage for genomic tests, leaving private patients to spend three months’ wages on a single BRCA assay. Even in the United States, high-deductible plans shift USD 1,000 or more to patients, leading 23% of eligible individuals to forego testing in 2025. Manufacturers are rolling out slimmed-down 50-gene panels priced near USD 1,000, but these miss actionable mutations in almost one in five cases.   

Limited Reimbursement in Low-Income Nations

Health ministries in low- and middle-income countries still prioritize infectious disease and maternal health, delaying reimbursement for cancer diagnostics. Nigeria’s national scheme covers only 4% of the population and finances basic pathology while excluding molecular tests, contributing to 68% of cancers being discovered at stage III or IV. Bangladesh added mammography to its essential benefits in 2024 but had no budget for equipment in 58 of 64 districts. Indonesia reimburses liquid-biopsy assays at USD 150, just 5% of commercial pricing, so laboratories opt out, and patients must self-pay. The World Bank disbursed USD 340 million in 2025 for screening pilots across a dozen nations, but most programs remain grant-funded rather than embedded in domestic insurance systems.  

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Diagnostic Type: Liquid Biopsies Gain While Immunoassays Anchor Revenue

IVD immunoassays contributed 53.22% to 2025 revenue, supported by high-throughput analyzers that process up to 400 samples an hour at unit costs below USD 5.^{[3]U.S. Food and Drug Administration, “Breakthrough Devices Program,” FDA.GOV} Genomic and liquid-biopsy platforms are projected to expand at 9.29% yearly through 2031 as coverage decisions proliferate and standard turnaround time drops to under 48 hours. Diagnostic imaging retains a mid-teens share and benefits from AI algorithms that reduce false positives by 22%, encouraging radiologist adoption. Biopsy and cytology test volumes are plateauing because oncologists now use blood-based assays for therapy selection, eliminating repeat tissue procedures. Tumor biomarker tests remain indispensable for ongoing monitoring, but grow more slowly than the overall cancer diagnostics market. 

Margin profiles vary widely. Immunoassay vendors earn stable reagent revenue from broad installed bases, while genomic firms rely on intellectual-property-protected data analytics. Illumina’s NovaSeq X lowered sequencing cost per genome to USD 200, enabling laboratories to price comprehensive panels at USD 1,500 with 40% gross margins. Thermo Fisher Scientific’s sample-to-answer PCR unit delivers 28-gene detection in four hours without manual extraction, opening molecular testing to community hospitals lacking specialist staff. Regulators reinforce momentum; the FDA cleared 17 breakthrough oncology platforms in 2025, and the European Medicines Agency cut nine months off average review timelines for assays with strong clinical evidence. Consequently, immunoassays will continue to anchor revenue, but liquid biopsies will capture most incremental growth, reshaping the cancer diagnostics market by 2031.

By Cancer Type: Lung Cancer Diagnostics Accelerate on Screening Expansion

Breast cancer accounted for 26.58% of 2025 revenue, as long-standing screening guidelines ensure steady volumes for mammography, ultrasound, and genomic panels. Lung cancer diagnostics are poised to grow fastest at 9.97% through 2031, driven by expanded low-dose CT eligibility and emerging blood-based early-detection assays. The U.S. Preventive Services Task Force broadened its criteria in 2024, adding 6.4 million eligible adults, while China mandated annual CT scans for 87 million smokers in 2025. Colorectal diagnostics gain from stool-DNA tests that deliver 92% sensitivity for advanced adenomas, pushing adherence among Medicare beneficiaries to 78%.

Prostate screening is under review, yet MRI-guided biopsies launched in 2024 have significantly reduced overdiagnosis, improving payer acceptance. Low-resource settings shift cervical screening to HPV DNA tests, as Roche processed 14 million samples across India and Sub-Saharan Africa in 2025. Liver and pancreatic diagnostics remain small but promising, following a 2025 trial that reported 83% sensitivity for liquid biopsy methylation assays in early-stage pancreatic tumors. Ovarian screening still lacks high-specificity tools, and the USPSTF issued a grade D recommendation against population testing. Kidney and bladder detection hinges on incidental imaging and cystoscopy, keeping growth subdued. Segment momentum therefore pivots on technology readiness and policy alignment rather than incidence alone, propelling lung testing ahead within the cancer diagnostics market.  

By End User: Ambulatory Centers Gain as Testing Decentralizes

Hospitals accounted for 53.14% of spending in 2025, thanks to capital budgets for imaging suites and sequencing labs. Yet ambulatory and point-of-care sites are forecast to rise at 10.11% annually, fueled by compact immunoassay analyzers and handheld imaging devices. Large commercial laboratories leverage scale; Quest Diagnostics processed 178 million oncology tests in 2025 at costs 40% below hospital peers, preserving mid-twenties market share. Academic centers such as Memorial Sloan Kettering convert proprietary assays into national standards, exemplified by the MSK-IMPACT panel’s ascent in U.S. oncology workflows. 

Payment policy accelerates decentralization. CMS trimmed 2026 outpatient rates for imaging and lab services by 3.8% while raising ambulatory-surgery-center rates, creating a USD 150 to USD 300 per-test advantage outside hospital walls. U.S. retail chains respond; Walgreens will install diagnostic kiosks in 1,500 stores by 2027, while CVS Health co-locates blood-draw stations in 800 MinuteClinics. In India, chains such as Dr. Lal PathLabs opened 340 collection centers in tier-2 and tier-3 cities during 2025, lifting volumes 28%. Rural U.S. facilities face consolidation pressure as 19 hospitals closed in 2025, outsourcing complex testing to regional hubs. Decentralization thus re-balances procurement, but hospitals remain indispensable for multidisciplinary cases that integrate imaging, pathology, and oncology boards.

Geography Analysis

North America accounted for 39.26% of sales in 2025, underpinned by USD 12,500 per capita health spending and broad coverage for advanced diagnostics, whereas Asia-Pacific is set to rise at an 8.92% CAGR, the fastest regional pace. The regional cancer diagnostics market will sustain mid-single-digit growth as Medicare coverage for multi-cancer early detection took effect in 2026, adding 41 million reimbursed lives. The United Kingdom delayed the national liquid biopsy rollout due to a GBP 2.1 billion funding gap, signaling divergent adoption rates across Europe.

India’s Ayushman Bharat scheme covers 550 million citizens aged 50 and older. China’s domestic diagnostic chains now run 1,800 labs, driving local procurement and shortening installation cycles from 16 to six weeks. Japan’s shrinking population masks rising per-capita spending, which climbed 6.2% in 2025 after the government prioritized early detection to control late-stage therapy costs. South Korea’s screening program reached 76% participation in 2025, the highest globally, and newly reimbursed liquid-biopsy monitoring for colorectal survivors will support future test volumes. Australia expanded companion-diagnostic coverage in 2025, reinforcing a regional trend toward precision oncology reimbursement. 

The Middle East and Africa remain a low-single-digit share but show targeted investment. Saudi Arabia allocated USD 1.2 billion under Vision 2030 to install 45 PET-CT scanners and set up genomic labs in three major cities. The United Arab Emirates is establishing oncology centers that integrate AI pathology, aiming to serve medical tourists. South America presents mixed signals; Brazil’s national system added mammography and colonoscopy to coverage in 2024, yet equipment shortages persist in northern states. Overall, while North America and Europe still drive absolute revenue, Asia-Pacific will contribute most net new spending, reshaping competitive focus within the cancer diagnostics market.

Regulatory Landscape

The U.S. FDA's Oncology Center of Excellence continues to shape oncology in vitro diagnostics through ongoing PMA activity and companion diagnostic oversight, with regulatory moves around high-impact assays shaping commercialization. FDA PMA approvals such as ColoSense (May 2025) and Alinity m HR HPV test (September 2025) anchor the integration of diagnostic and therapeutic decision-making in oncology.

Europe's IVDR transition continues to reset compliance timelines and Notified Body dependencies; a mid-2026 milestone arrived on May 26, 2026, when manufacturers of legacy Class C devices needed to submit formal applications to IVDR-designated Notified Bodies to access extended transition provisions. In China, the NMPA has updated oncology IVD expectations through cancer-screening clinical evaluation guidance (August 2025) and more recent NGS-oriented review modernization, including draft registration review key points released in March 2026 and Technical Review Points for Tumor Gene Variation Detection Reagents (Trial) issued in June 2026, reinforcing local-evidence and method standardization requirements for tumor mutation detection reagents.

Market Opportunities and Future Outlook

Consolidation and workflow integration create whitespace in end-to-end oncology testing as vendors bundle screening, genomic profiling, MRD monitoring, and pathology interpretation into fewer platforms and contracts. Quest Diagnostics is extending access through the OncoEMR platform with MRD ctDNA and comprehensive genomic profiling services (July 2026), reducing friction from test selection through results in oncology workflows. Regulatory and reimbursement catalysts add to commercial headroom, with Medicare nationwide coverage finalized in January 2026 for multi-cancer early-detection testing broadening reimbursed access, and legislative activity like H.R. 842 proposing Medicare coverage for MCED starting January 1, 2028 signaling continued emphasis on earlier detection.

Manufacturers and laboratories that can meet EU IVDR transition demands and China NMPA local-evidence expectations, while delivering faster turnaround and interoperable reporting, have clearer pathways to expand menus and placements across hospitals, independent labs, and decentralized care sites.